Sep 15, 2022 | 2022, Press Releases, Scientific
The study shows selective tumor uptake of IL12-7NP2 and potent antitumor activity as single agent and in combination with immune checkpoint inhibitors. The product is well tolerated when administered to non-human primates. More detailsJul 25, 2022 | 2022, Press Releases, Scientific
More detailsJun 27, 2022 | 2022, Past Events, Scientific
Philogen will attend the 3rd Annual Cytokine-Based Drug Development Summit in Boston. Roberto De Luca, Head of Antibody Therapeutics, will give a virtual lecture entitled “Antibody-cytokine fusion proteins against Fibroblast Activation Protein (FAP)” on the 28...Jun 27, 2022 | 2022, Events, Scientific
Philogen attends the Small Molecule Drug Discovery & Synthesis Symposium organized by Janssen in September 2022. Prof. Dario Neri, PhD, CEO and CSO of Philogen, to give a presentation entitled “From Encoded Combinatorial Libraries To Targeted Therapeutics” on the...Jun 27, 2022 | 2022, Events, Scientific
Philogen attends the Festival of Biologics in Basel in November 2022. Roberto De Luca, PhD, Head of Antibody Therapeutics at Philogen, to give a presentation entitled “Tripokin: tumor targeted delivery of IL2 potentiated by TNF”. Samuele Cazzamalli, PhD, Head of Small...Jun 27, 2022 | 2022, Events, Scientific
Philogen attends the Symposium on DNA-Encoded Chemical Libraries in November 2022. Prof. Dario Neri, PhD, CEO and CSO of Philogen, to give a presentation entitled “Quantification of DEL selections and implications for good selection protocols” on November 3. Please...
Recent Comments